Hemodynamic Surveillance

Hemodynamic Surveillance Platform

Early physiological trajectory detection from routinely available signals.

Aranga identifies hemodynamic instability risk before overt vital sign deterioration, enabling earlier clinical decision-making in critical care settings.

Standard Monitor: Blood PressureNORMAL
14012010080
120/80mmHg
Aranga: Perfusion Cost IndexDANGER
20015010050
186PCI↑ Critical

Standard monitors see 120/80. We see the metabolic cost.

Aranga Biodynamics Ltd • 9 Patents Pending

Core Technology

Hemodynamic Surveillance Platform

A physics-informed approach to patient monitoring that identifies risk patterns in vital sign trajectories.

Physics-Based

Physiological Efficiency

Analyzes cardiovascular effort, not just output. Our physics-informed models reveal how hard the system is working to maintain stability.

Early Warning

Trajectory Detection

Identifies deterioration patterns in retrospective evaluation before overt vital sign changes. Lead-time metrics available under NDA.

Configurable

Calibrated Risk Scoring

Distinguishes concerning states from safe compensatory responses with probability-calibrated outputs and configurable alert thresholds.

Patent Pending

Signal Processing Heritage

Signal processing techniques adapted from defense research applications, designed for detecting subtle patterns in noisy physiological data.

Trajectory-Based vs Threshold-Based Detection

Early
Trajectory Signal
Pattern Identified
Escalating
Risk Increasing
Decision Window
Threshold
Vital Sign Alert
Standard Detection
Cross Domain Knowledge Application

From Deep Sea to Deep Physiology

Military-grade signal processing, adapted for the most critical mission: saving lives.

Anti-Submarine Warfare

Passive Sonar Processing

The Challenge: Detect a quiet submarine hiding in ocean noise before it becomes a threat.

The Signal: Subtle changes in “acoustic signature” patterns that reveal position and intent.

The Method: Track faint signatures over time, correlate multiple sensors, detect before breach.

“Hunt the submarine before it fires.”

Hemodynamic Surveillance

Perfusion Cost Analysis

The Challenge: Detect compensated shock hiding behind normal vital signs before the patient crashes.

The Signal: Subtle changes in “metabolic cost” that reveal physiological strain.

The Method: Track efficiency patterns over time, correlate multiple vitals, detect before crash.

“Hunt the instability before it kills.”

We treat the patient like a “Quiet Submarine”—detecting the “acoustic signature” (Metabolic Cost) before they emit an active signal (Hypotension).

The same algorithms that protect naval fleets now protect your patients.

Three-Layer Architecture

Aranga integrates physics-based analysis, deterministic governance controls, and configurable clinical constraints within a single auditable platform.

Layer 1: Physics

The Physics Engine

Standard monitors measure status (Blood Pressure, Heart Rate, Respiratory Rate etc). Aranga measures effort. Our Perfusion Cost Analysis™ quantifies the metabolic energy required to maintain stability—detecting the "Walking Wounded" before they crash.

Layer 2: Governance

The Governance Engine

Decision support systems must have strong governance guardrails. Safety requires "Hard Veto." Multiple inference models monitor the patient—if any single model detects a critical threat, it locks into RED ALERT. A stable heart rate can never mask a fatal blood pressure.

Layer 3: Cultural Safety

The Cultural Safety Layer

Medicine is not just biology—it is ethics, law, and geography. The External Constraint Interface allows health districts to inject specific protocols directly into the decision logic, ensuring care is equitable and culturally safe.

Universal Safety Net

The Complete Cardiovascular Governance System

Aranga isn't just a shock monitor—it's a multi-disease safety net with the architectural breadth to manage the entire patient journey from admission to discharge.

Shock States

Early Trajectory Detection

Hypovolemic Shock

Hemorrhage & Dehydration

Detects rapid rise in metabolic cost as the body compensates to maintain pressure during blood or fluid loss.

Septic Shock

Distributive Failure

Arterial Stiffness Analysis distinguishes "Warm Shock" (vasodilation) from other shock types.

Cardiogenic Shock

Pump Failure

Detects when heart rate compensation is failing, triggering Hard Veto even when other vital signs appear stable.

Occult Shock

The Walking Wounded

Detects instability in patients with normal blood pressure who are silently burning through physiological reserves.

Signal Intelligence

5 Patents Pending

Change-Point Detection

CUSUM Analysis

Detects slow sustained drift patterns before threshold breaches. A heart rate drifting 75→85→95 over 6 hours triggers detection even though no single value is alarming.

Trajectory Integration

Track-Before-Detect

Validates vital sign patterns against expected clinical trajectories. Accumulates "energy" along velocity vectors to detect momentum-based deterioration.

Syndrome Detection

Stealth Signatures

Detects syndrome patterns across multiple vitals simultaneously. Individual vitals may be borderline, but the combination reveals deterioration.

Coupling Assessment

Physiological Coherence

Monitors natural correlations between vital signs. Loss of coupling (decoherence) indicates autonomic failure before vital signs change.

Temporal Synchronization

Unified Reference Frame

Heart rate arrives every minute, lactate every 6 hours, vasopressor boluses unpredictably. Our proprietary system creates a unified temporal reference for precise event correlation.

Renal & Fluid Management

Reduced Alert Burden

Acute Kidney Injury

False Alarm Prevention

Hemodynamic Decoupling correctly identifies patients as stable despite abnormal renal markers.

Fluid Overload

Pulmonary Edema Prevention

Vascular Stiffness Interlock VETOES fluid administration in volume-intolerant patients to prevent drowning the lungs.

Dialysis Optimization

Dry Weight Estimation

Uses perfusion curve inflection point to determine optimal dry weight during dialysis with precision.

Complex & Comorbid Scenarios

Edge Case Coverage

Opioid Suppression

Sedation-Proof Surveillance

Detects deterioration even when heart rate and respiratory drive are chemically suppressed by pain medication.

Iatrogenic Prevention

Doctor-Caused Harm

Nash Consensus Governance prevents unsafe interventions like giving fluids to heart failure patients.

Cultural Constraints

Ethical Care Boundaries

Constraint Injection Interface loads religious and ethical protocols like bloodless medicine thresholds.

Clinical Application Spectrum

A platform designed to address multiple clinical scenarios across the patient journey.

Sepsis

Late Alert (after BP drop)
4-Hour Pre-Alert (Metabolic Cost)

Renal Failure

Constant False Alarms
Stable GREEN (Decoupled Logic)

Fluid Overload

"Guess and Check"
Hard Veto (Stiffness Interlock)

Dialysis

Manual Weight Guesses
Perfusion Inflection Point

Sedation

Suppressed Vitals = Blind
Metabolic Decoupling

Remote Care

"Fly Blind"
Military-Grade Surveillance

Aranga isn't just a monitor—it's a Safety Net for the entire hospital.

Retrospective Evaluation

Evaluated on multiple international datasets to assess performance across different populations and clinical contexts. Detailed metrics available under NDA.

Scale

MIMIC-IV

United States

Retrospective evaluation on US critical care dataset for statistical power.

Large critical care cohortMetrics under NDA
Fidelity

VitalDB

Korea

Perioperative waveform data for signal processing validation.

High-resolution waveformsWaveform analysis
Diversity

Multi-center

International

Cross-demographic evaluation to assess generalization.

Multiple institutionsDetails under NDA
Illustrative Examples

Retrospective Case Analysis

The following examples illustrate system behavior patterns observed in retrospective evaluation. These are not prospective clinical outcomes. Actual performance metrics and methodology are available under NDA.

Case 1 — True Positive

Silent Pump Failure

NZEWS Assessment
T+0hScore 2 — Routine observation
T+2hScore 3 — Increased frequency
T+4hScore 7 — MET call triggered
Aranga Assessment
T+0hPCI 142 — Elevated efficiency cost detected
T+45minCardiogenic phenotype: 78% confidence
T+1hAlert: “Consider echo — pump efficiency declining”

Retrospective Observation: Patient had EF 25% on subsequent echo. In this retrospective case, Aranga identified elevated efficiency cost prior to EWS threshold breach, while BP appeared stable. (Illustrative example; not a prospective outcome claim)

Case 2 — True Positive

Warm Shock Signature

NZEWS Assessment
T+0hScore 1 — Low risk
T+3hScore 2 — Mild tachycardia noted
T+6hScore 8 — Hypotension onset
Aranga Assessment
T+0hVasoplegic pattern detected — low SVR signature
T+30minDistributive phenotype: 82% confidence
T+1hAlert: “Sepsis workup recommended”

Retrospective Observation: Blood cultures confirmed E. coli. In retrospective analysis, Aranga identified a distributive pattern prior to overt hypotension. (Illustrative example; clinical utility requires prospective validation)

Case 3 — False Alarm Prevention

Physics Veto

Standard Monitor Alert
EventHR 128 — Tachycardia alarm triggered
ResponseRapid response team activated
FindingPatient anxious, post-procedure
Aranga Assessment
PCI87 — Normal efficiency range
Physics CheckCardiac output appropriate for HR
StatusNo alert — Compensatory response

System Behavior: Physics-based analysis confirmed cardiac efficiency was maintained despite elevated HR. The system's governance logic suppressed alerting for this compensatory response. (Example of specificity optimization; alarm reduction metrics under NDA)

Case 4 — Phenotype Guidance

Shock Etiology Classification

Current Practice
Detection“Patient is deteriorating”
WorkupBroad differential, multiple tests
Time to DxHours to identify shock type
Aranga Assessment
Detection“Cardiogenic pattern detected”
WorkupTargeted: Echo, BNP, troponin
ClassificationPhenotype probability output

Capability: Phenotype classification provides probability estimates across shock etiologies. This may support targeted workup prioritization. (Classification accuracy metrics available under NDA)

Case 5 — Biomarker Integration

BNP Override

Initial Assessment
ArangaDistributive phenotype: 65%
ConfidenceModerate — mixed signals
RecommendationSepsis workup initiated
After BNP Result
BNP2,847 pg/mL (elevated)
Aranga UpdateCardiogenic phenotype: 89%
New RecommendationEcho and cardiology consult

Integration Capability: The system can incorporate laboratory values when available to refine phenotype probability estimates. This example shows how biomarker data can shift classification confidence. (Example of multi-modal integration capability)

Case 6 — Preventable Harm

The “Lag Time” Trap

A 78-year-old female presents with “general malaise” and poor oral intake. Triage vitals are deceptively reassuring.

Standard Care Reality
TriageNZEWS 0 — “Stable”
BP 115/65, HR 88. Placed in waiting room (Cat 4)
T+4hNZEWS 1 — “Still Stable”
BP 108/60, HR 94. Finally seen, bloods drawn
T+6hCreatinine 280 — AKI Stage 3
Admitted for IV fluids. 5-day hospital stay
Aranga Assessment
TriageRESISTIVE PHENOTYPE
High Stiffness (1.76) + Compensatory Rate
RiskOccult hypoperfusion detected
T+4hRENAL WINDOW CLOSING
Sustained high-cost perfusion detected (PCI > 140)
Alert“Damage preventable at Triage”

Retrospective Observation: In this retrospective case, the patient had a low EWS score at triage. The system identified a resistive phenotype pattern at initial assessment. (Illustrative example; prospective validation required to assess clinical utility)

Validation Summary

Multi
Dataset Evaluation
AUROC
Discrimination Metrics
AUPRC
Precision-Recall Analysis
NDA
Detailed Metrics Available

Retrospective evaluation on multiple datasets. Specific performance metrics, lead-time analysis, and methodology documentation available under NDA. Prospective validation planned.

Universal Physiology

Safety for Every Phenotype

“Aranga” means to rise in te reo Māori. We built a system that works for everyone—not just the populations overrepresented in training data.

Vascular Diversity Calibration

Calibrated across diverse patient populations. Our Stiffness Interlock ensures accurate readings for patients with varying vascular profiles.

Rheumatic Heart Disease

Patients with RHD have different vascular characteristics. Aranga's physics engine adapts to these phenotypes rather than assuming Western baselines.

Indigenous Health Equity

Standard AI is biased toward Western datasets. Aranga is validated across diverse demographics to ensure equitable care for all populations.

Cultural Protocol Injection

The External Constraint Interface loads religious and ethical protocols—from bloodless medicine thresholds to cultural care boundaries.

Whether your patient is in a metro ICU or a remote rural clinic, Aranga is designed to support equitable and culturally appropriate clinical decision-making.

Evaluated on multiple international datasets. Site-specific protocols configurable.

Command Console

The Aranga Interface

Purpose-built for high-stakes clinical environments. Configurable alert thresholds.

ARANGABIODYNAMICSv3.2.0
Hysteresis:Active
Physics:Stable
Patient: BED-A1wardICUCriticalSeptic shock (suspected)
PCI Trend
PCI Line Yellow Red (PCI) Red (BP) Vasopressor Fluid Blood
200150100500
IMM Shock Probability
Shock % Yellow Red (PCI) Red (BP) Vasopressor Fluid Blood
100%75%50%25%0%
Heart Rate
-16.1/hr
118 bpm
IMM: stress
SBP
-16.5/hr
88 mmHg
IMM: shock
MAP
-66.8/hr
62 mmHg
IMM: shock
Shock Index
→ 0.0/hr
1.3
Elevated
Clinical Modes
Heart Ratestress (78%)
Blood Pressureshock (92%)
MAPshock (68%)
Combined Shock Probability87%
Shock Etiology Diagnosis
Septic (Distributive)
Confidence:
72%
EVIDENCE
• Wide pulse pressure phenotype
• Distributive signature match (72%)
Alert Comparison
EWS (STANDARD)
6
EWS 6-7
Review: Every 1hr
ARANGA PCI
RED
PCI: 186
High shock probability
ARANGA ALERT HISTORY
14:23 - RED Alert triggered
10:15 - DRIFT detected

Partner With Us

Request technical documentation including detailed performance metrics, integration specifications, and evaluation methodology under NDA.

For engineering, clinical affairs, and regulatory teams evaluating integration.